New guidelines from the British Society for Haematology (BSH) offer a less restrictive approach to the use of DOACS in antiphospholipid syndrome (APS) compared to recent regulatory agency bans. In 2019 medicine regulators including the TGA recommended that DOACS should not be used in patients with APS, after extrapolating results from the TRAPS1 study that ...
Guidelines offer nuanced approach to use of DOACs in antiphospholipid syndrome
By Michael Woodhead
23 Jan 2020